3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director

3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director, leading quality control, quality assurance and analytical departments

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of Ricardo Izquierdo as Quality Director.

3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director, leading quality control, quality assurance and analytical departments

Ricardo Izquierdo has a solid experience as a quality director and joins 3P Biopharmaceuticals with the aim of encompassing and monitoring the entire quality chain in the company.

He has spent over 30 years working in leadership positions within Quality Assurance and Quality Control departments in companies such as Famar Healthcare Services, Crucell, Lapis Lazuli International, Avizor, Inmunotek, Inmunal and Unolab Manufacturing.

He brings with him a strong background in Quality within the pharmaceutical industry having served as a Qualified Person, Manager, and Head of Quality in various Quality Control and Quality Assurance organizations.

He began his career in 1990 at Inmunal as a Quality Director and since then he has not stopped developing his knowledge and skills in the field of Pharmaceutical Quality.

Therefore, his professional career has been developed in GMP environments, and he is an expert in design, development and implementation of Pharmaceutical Quality systems, as well as in the management and obtaining of Medicines Licences (MAH).

He also has expertise; among others, in sterile medicine manufacturing, implementation of quality standards, and biological products for human use (vaccines).
Before joining the 3P team, he was Head of Quality at Famar.

I am grateful for the opportunity to continue building and developing a full quality strategy that allows 3P to advance its position as the leading CDMO in Europe” said Ricardo upon arrival at the Noain-based company.

Dámaso Molero, CEO at 3P Biopharmaceuticals said: “We are very pleased to welcome Ricardo Izquierdo to our team. His great experience as a quality manager will help us lead the entire 3P quality process and provide the best CDMO service in the market“.

Therefore, with this new addition to the management team,3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.

View the full press release here

Related Content

3P Biopharmaceuticals makes a significant donation to help Ukraine

The donation is an employee initiative and is supported by the company.
Read more

Dámaso Molero, appointed member of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra.

Navarra advances in the Comprehensive Strategy for Personalized Medicine with the constitution of the body that will coordinate its execution.
Read more

Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2

Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.